Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory biomarker study of Vargatef in adenocarcinoma NSCLC
NL-OMON46049Phase 4Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Overall survival. Started Apr 2016; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on NL-OMON46049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46049.